General Info

HemoGenix has developed the HALO Kit Platform with more than 360 different kit variations and multiple formats. In 2003, the company relocated from Columbia, S.C., to Colorado Springs, Colo., in order to expand the company and begin production of the HALO Kit Platform. The HALO Platform was developed because of the need for a stem cell hemotoxicity detection system with a rapid, nonsubjective and standardized output with high-throughput capability that could be used at all stages of drug discovery and development. HemoGenix was founded in March 2000 by an internationally recognized researcher in the field of developmental, experimental and applied clinical hematology.